Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into a Contract Services Agreement

    TORONTO, March 1 /CNW/ - Dalton Pharma Services, a privately owned
Canadian pharmaceutical services provider to leading pharmaceutical companies,
today announced the company has entered into a Contract Services Agreement
with Affectis Pharmaceuticals AG, of Munich, Germany.
    Affectis has contracted Dalton for the manufacturing of preclinical tox
material with potential for cGMP production. Affectis is an exciting addition
to Dalton's portfolio of world wide clients. Dalton has first hand experience
advancing compounds from a range of therapeutic areas including Alzheimer's,
cardiovascular diseases, HIV, anti-aging and now also affective disorders.
    "Our relationship with Affectis was solidified upon the successful
completion of Health Canada's audit of our manufacturing facilities," said
Peter Pekos, President and CEO of Dalton Pharma Services. "We have recently
attained an Establishment License from Health Canada, a milestone which will
allow Dalton Pharma Services to manufacture sterile products, test and ship
commercial products for our existing clients in Canada and also the European
Union. We are confident the Establishment License will attract and fulfill
other commercial pharmaceutical manufacturing relationships within the EU. We
look forward to a successful collaboration with Affectis," continued Peter
    "With this agreement, Affectis reaches an important milestone of
advancing its P2X7 agonist program into pre-clinical development" said Herbert
Stadler, CEO of Affectis. "Dalton's manufacturing know-how will help Affectis
bring a novel antidepressant candidate into the clinic."

    About Dalton Pharma Services

    Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a
contract pharmaceutical manufacturer that supplies chemistry and analytical
services to the biotechnology and pharmaceutical industries in the areas of
medicinal chemistry, fine chemical manufacture, custom peptides and antisense
oligo production. Dalton provides cGMP manufacturing and sterile filling
services to its customers at any stage of the regulatory process (Phase I, II,
III or commercial). In its state of the art cGMP facilities, Dalton can
produce active pharmaceutical ingredients (API), at the gram or kilogram
scale. Dalton can carry out sterile fills to produce batches of finished drug
product in vials or syringes, either aseptically filled or terminally
sterilized, under fully validated conditions. In addition to drug testing,
Dalton's analytical chemistry laboratory offers method development,
validation, ICH stability programs and HPLC-MS services to its clients.

    About Affectis Pharmaceuticals AG

    Affectis is a biopharmaceutical company implementing novel concepts for
the treatment of mental disorders, especially depression and schizophrenia.
The Company has unique capabilities to discover and develop drugs based on
pioneering findings in the field of mental disorders. These drugs address the
increasing need for more comprehensive and faster-acting antidepressants with
fewer side effects. Affectis started operations in November 2003 as a spin-off
from the renowned Max-Planck-Institute of Psychiatry, a world leader in the
field of psychiatric research. A strong team of executives and scientists with
long-term industry experience contribute to Affectis' progress. The Company
raised its third round of venture financing in October 2006, led by AESCAP
Venture. Affectis is based in Munich, Germany. www.affectis.com

For further information:

For further information: Peter Pekos, Dalton Pharma Services, Tel: (416)
661-2102, Fax: (416) 661-2108, ppekos@dalton.com; Sabina van den Brandt,
Affectis Pharmaceuticals AG, Tel: +49 (0)89-306 22-591, Fax: +49 (0)89-306
22-370, contact@affectis.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890